Sign Out
Pregnancy: Slinda should not be used during pregnancy.
If pregnancy occurs during treatment with Slinda, further intake should be stopped.
Epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used drospirenone prior to pregnancy, nor a teratogenic effect when drospirenone was taken inadvertently during pregnancy.
Animal studies have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Based on these animal data, undesirable effects due to hormonal action of the active compound cannot be excluded.
Breastfeeding: Negligible amounts of drospirenone are excreted in the breast milk. The daily dose of drospirenone in the baby is <1% of the maternal dose. Thus, at therapeutic doses of Slinda, no effects on the breastfed newborns/infants are anticipated. Based on the available data, Slinda may be used during lactation.
Fertility: Slinda is indicated for the prevention of pregnancy.
Continue with Google